ClinVar Miner

Submissions for variant NM_006231.4(POLE):c.1107-3C>T

gnomAD frequency: 0.00001  dbSNP: rs369572563
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000606137 SCV000731272 uncertain significance not specified 2016-11-22 criteria provided, single submitter clinical testing The c.1107-3C>T variant in POLE has not been previously reported in individuals with colorectal cancer or in large population studies. This variant is located i n the 3' splice region. Computational tools do not suggest an impact to splicing . However, this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the c.1107-3C>T variant is uncertain.
Invitae RCV003767740 SCV000772839 uncertain significance not provided 2023-12-29 criteria provided, single submitter clinical testing This sequence change falls in intron 11 of the POLE gene. It does not directly change the encoded amino acid sequence of the POLE protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs369572563, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 517160). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV001009907 SCV001170035 uncertain significance Hereditary cancer-predisposing syndrome 2018-06-21 criteria provided, single submitter clinical testing The c.1107-3C>T intronic variant results from a C to T substitution 3 nucleotides upstream from coding exon 12 in the POLE gene. This nucleotide position is poorly conserved in available vertebrate species. Using the BDGP splice site prediction tool, this alteration is not predicted to have any significant effect on this splice acceptor site while the ESEfinder splice site prediction tool predicts a slight weakening in the native splice acceptor site efficiency; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.